- Home
- LGVN vs CGTX Comparison
LGVN vs CGTX Comparison
Compare LGVN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- CGTX
- Stock Information
- Founded
- LGVN 2014
- CGTX 2007
- Country
- LGVN United States
- CGTX United States
- Employees
- LGVN N/A
- CGTX N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- CGTX Health Care
- Exchange
- LGVN Nasdaq
- CGTX Nasdaq
- Market Cap
- LGVN 23.4M
- CGTX 20.5M
- IPO Year
- LGVN 2021
- CGTX 2021
- Fundamental
- Price
- LGVN $1.30
- CGTX $0.32
- Analyst Decision
- LGVN Strong Buy
- CGTX Strong Buy
- Analyst Count
- LGVN 3
- CGTX 5
- Target Price
- LGVN $8.67
- CGTX $5.63
- AVG Volume (30 Days)
- LGVN 138.8K
- CGTX 1.9M
- Earning Date
- LGVN 08-13-2025
- CGTX 08-07-2025
- Dividend Yield
- LGVN N/A
- CGTX N/A
- EPS Growth
- LGVN N/A
- CGTX N/A
- EPS
- LGVN N/A
- CGTX N/A
- Revenue
- LGVN $2,225,000.00
- CGTX N/A
- Revenue This Year
- LGVN N/A
- CGTX N/A
- Revenue Next Year
- LGVN $51.48
- CGTX N/A
- P/E Ratio
- LGVN N/A
- CGTX N/A
- Revenue Growth
- LGVN 127.50
- CGTX N/A
- 52 Week Low
- LGVN $1.14
- CGTX $0.22
- 52 Week High
- LGVN $6.40
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- LGVN 50.13
- CGTX 54.36
- Support Level
- LGVN $1.15
- CGTX $0.25
- Resistance Level
- LGVN $1.32
- CGTX $0.33
- Average True Range (ATR)
- LGVN 0.09
- CGTX 0.03
- MACD
- LGVN 0.01
- CGTX 0.00
- Stochastic Oscillator
- LGVN 45.31
- CGTX 91.98
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.